Literature DB >> 9014160

Chimeric GABAA/glycine receptors: expression and barbiturate pharmacology.

V V Koltchine1, Q Ye, S E Finn, N L Harrison.   

Abstract

GABAA and glycine receptors are close relatives in the "gene superfamily" of ligand-gated ion channels, but have distinctly different pharmacology. For example, barbiturates have two effects on GABAA receptors (GABAA-R): at low micromolar concentrations (2-5 microM), the anesthetic barbiturate methohexital potentiates submaximal chloride current responses to GABA; at higher concentrations (20-50 microM), the barbiturate causes direct gating of the channel in the absence of agonist. Neither of these barbiturate effects is seen on the glycine receptor (Gly-R). In order to study the structural parts of the GABAA-R involved in this barbiturate pharmacology, two unique restriction sites were introduced into the cDNAs encoding the alpha 2 and beta 1 subunits of the human GABAA-R and the alpha 1 subunit of the human gly-R. The first site ('X') corresponded to the C-terminal end of the third transmembrane domain (M3) in each subunit and enabled exchange of C-terminal fragment of approximately 100 amino acids (which includes the large 'cytoplasmic loop' and M4 segment) between GABAA-R and Gly-R subunits. The second site ('S') was approximately 30 amino acids 3'- from the N-terminal end of each subunit and enabled exchange of a small N-terminal fragment between GABAA-R and Gly-R subunits. Several chimeric receptor subunit cDNAs were constructed and the resulting receptors tested for their ability to respond to GABA and glycine and for sensitivity to the barbiturate methohextial (MTX). The results show that neither the large C-terminal fragment nor the smaller N-terminal fragment is associated with the enhancement or direct activation of the GABAA-R by MTX. These results demonstrate the viability of chimeric GABAA/Gly-R and suggest that the method will be suitable for further investigation of the molecular basis of the barbiturate pharmacology of the GABA-R.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9014160     DOI: 10.1016/s0028-3908(96)00088-3

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

Review 1.  General anaesthetic actions on ligand-gated ion channels.

Authors:  M D Krasowski; N L Harrison
Journal:  Cell Mol Life Sci       Date:  1999-08-15       Impact factor: 9.261

2.  The actions of ether, alcohol and alkane general anaesthetics on GABAA and glycine receptors and the effects of TM2 and TM3 mutations.

Authors:  M D Krasowski; N L Harrison
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

3.  Alpha subunit isoform influences GABA(A) receptor modulation by propofol.

Authors:  M D Krasowski; S M O'Shea; C E Rick; P J Whiting; K L Hadingham; C Czajkowski; N L Harrison
Journal:  Neuropharmacology       Date:  1997-07       Impact factor: 5.250

4.  Mice devoid of gamma-aminobutyrate type A receptor beta3 subunit have epilepsy, cleft palate, and hypersensitive behavior.

Authors:  G E Homanics; T M DeLorey; L L Firestone; J J Quinlan; A Handforth; N L Harrison; M D Krasowski; C E Rick; E R Korpi; R Mäkelä; M H Brilliant; N Hagiwara; C Ferguson; K Snyder; R W Olsen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

5.  Gamma-aminobutyric acid increases the water accessibility of M3 membrane-spanning segment residues in gamma-aminobutyric acid type A receptors.

Authors:  D B Williams; M H Akabas
Journal:  Biophys J       Date:  1999-11       Impact factor: 4.033

6.  The sleep hormone oleamide modulates inhibitory ionotropic receptors in mammalian CNS in vitro.

Authors:  Leanne Coyne; George Lees; Russell A Nicholson; Jian Zheng; Katherine D Neufield
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

7.  Piracetam and TRH analogues antagonise inhibition by barbiturates, diazepam, melatonin and galanin of human erythrocyte D-glucose transport.

Authors:  Richard J Naftalin; Philip Cunningham; Iram Afzal-Ahmed
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.